🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Bristol-Myers Squibb stock gains after raising full-year guidance

Published 26/07/2024, 09:56 pm
© Reuters.
BMY
-

Bristol-Myers Squibb (NYSE:BMY) shares rallied more than 5% premarket Friday as the company reported a robust second quarter, surpassing Wall Street's expectations for both earnings and revenue, and raised its full-year guidance.

The pharmaceutical giant posted adjusted earnings per share (EPS) of $2.07, significantly higher than the analysts' estimate of $1.64. Revenue for the quarter was also strong at $12.2 billion, beating the consensus estimate of $11.52 billion and marking a 9% increase from the same quarter last year, or an 11% rise adjusting for foreign exchange.

The company's performance was propelled by its Growth Portfolio, which saw revenues climb to $5.6 billion, an 18% jump, or 21% when considering foreign exchange adjustments.

This increase was mainly due to robust demand for products like Opdivo, Reblozyl, Camzyos, and Opdualag, although partially offset by Abecma. The Legacy Portfolio also contributed with a 2% revenue increase, driven by Eliquis and Pomalyst, despite a decline in Revlimid due to generic competition.

Bristol Myers Squibb's raised guidance reflects confidence in its trajectory, with the company now expecting adjusted EPS for 2024 to be between $0.60 and $0.90, compared to the previous range of $0.40 to $0.70. This updated guidance is well above the analysts' consensus of $0.51, signaling a positive outlook for the company's financial performance.

The company also now sees full-year revenue in the upper end of the low single-digit range, higher than the previously forecast low single-digit increase.

"Our second quarter results reflect progress against our strategy to position BMS for long-term, sustainable growth," said Christopher Boerner, board chair and chief executive officer. "We're also driving operational excellence throughout the company, becoming more agile and strengthening execution."

The positive market response underscores investor confidence in Bristol Myers Squibb's growth strategy and its ability to deliver on its promises. The company's focus on operational excellence and its pipeline of promising treatments, including the anticipated U.S. launch of KarXT and recent approvals for Breyanzi, position it well for continued success.

The company's financial health was further evidenced by a gross margin increase on an adjusted basis from 75.0% to 75.6% due to favorable product mix, despite a decrease in GAAP gross margin primarily due to a one-time impairment charge.

Additionally, the company's effective tax rate on an adjusted basis improved from 16.9% to 14.1%, mainly due to the release of income tax reserves.

As Bristol Myers Squibb moves into the second half of the year, its raised guidance and strong second-quarter performance indicate a positive trajectory, with the stock market reflecting this optimism through the significant uptick in share price.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.